Session 11: The Latest and Greatest in IO

Sunday, September 25, 2022

10:15 AM – 11:15 AM

Location: Americana 3

Discussant(s)

Ghassan Abou-Alfa, MD, MBA

Professor
Memorial Sloan Kettering Cancer Center
New York, New York
Daniel Brown, MD, FSIR

Vice-Chair, Innovation and Clinical Research
Interventional Oncology
Vanderbilt University Medical Center
Vanderbilt University Medical Center
Nashville, Tennessee
Edward Kim, MD

Professor of Radiology and Surgery
Mount Sinai Health System
Icahn School of Medicine at Mount Sinai
New York, New York

10:15 AM – 10:25 AM

The Most Influential Publications in the Last Year
Speaker: William S. Rilling, MD, FSIR – Medical College of Wisconsin/Froedtert Hospital
10:25 AM – 10:33 AM

CIO Abstract: Embolization of Primary and Secondary RCC Tumors with the GPX Embolic Device
Speaker: Ryan G. O'Hara
10:33 AM – 10:41 AM

CIO Abstract: Atezolizumab + bevacizumab vs sorafenib in HCC patients with prior locoregional therapy: IMbrave150 Exploratory Data
Speaker: Riad Salem, MD, MBA – Northwestern University Feinberg School of Medicine
10:41 AM – 10:49 AM

CIO Abstract: Transarterial Chemoembolization ± (Tremelimumab and Durvalumab ± Lenvatinib) in Hepatocellular Carcinoma: EMERALD-3
Speaker: Ghassan K. Abou-Alfa, MD, MBA – Memorial Sloan Kettering Cancer Center
10:49 AM – 10:57 AM

CIO Abstract: Updated Clinical and Dosimetric Recommendations for Yttrium-90 Glass Microspheres in Hepatocellular Carcinoma (HCC)
Speaker: Edward Kim, MD – Mount Sinai Health System
10:57 AM – 11:10 AM

Discussion/Audience Q&A
Discussant: Ghassan K. Abou-Alfa, MD, MBA – Memorial Sloan Kettering Cancer Center
Discussant: Edward Kim, MD – Mount Sinai Health System
Discussant: Daniel Brown, MD, FSIR – Vanderbilt University Medical Center